Healthcare Innovation

A new partnership leverages in vivo screening to find novel obesity targets, aiming to revolutionize a market projected to exceed $100 billion.

Klotho Neurosciences will present its novel gene therapy for Alzheimer's and ALS at a key summit, seeking to turn scientific promise into clinical reality.

New data from a major Swedish study reveals SAGA Diagnostics' Pathlight test can predict colorectal cancer recurrence with remarkable accuracy, changing the game.

With its lead muscular dystrophy drug in late-stage trials, Edgewise Therapeutics heads to the JPM conference with high stakes for its pipeline and stock.

South Korea's Curogen secures major national funding and targets global partners at the JP Morgan conference, advancing novel therapies for IBD and HS.

In a major win, Rockwell Medical extends its DaVita supply deal through 2026 with a price hike, underscoring the value of its reliable supply chain.

A 41-year-old mother's massive heart attack on Valentine's Day sparked a miraculous story of survival, advanced medicine, and profound gratitude.

A new $1,000 grant aims to foster compassion in future doctors, but its founder, a prominent psychiatrist, recently pleaded guilty to healthcare fraud.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

Azenta divests its medical refrigeration unit to streamline its portfolio, signaling a strategic pivot to its high-growth multiomics and sample management services.

After a turbulent year, the sleep apnea device maker aims to prove its rocky product launch is behind it and convince investors of a strong 2026.

Dr. Philip Golinsky’s alumni award from Life University marks a milestone for RxWellness and the growing trend of integrated, non-surgical patient care.

Anixa Biosciences now fully controls its breast cancer vaccine after promising Phase 1 data. What does this strategic move mean for investors and medicine?

Aligos Therapeutics is using strategic stock grants to lure top talent. Is this a savvy growth play or a creeping cost for shareholders? We break it down.

In a market tired of hype, investors are rewarding verifiable results. We explore the tech delivering hard proof, from quantum security to cancer therapies.

Xtant Medical's new nanOss Strata bone graft isn't just an update; it's a strategic move to disrupt the orthobiologics market. Here's why it matters.

New data shows Kazia's paxalisib dismantles metastatic drivers and reignites immunity, signaling a strategic disruption in advanced breast cancer treatment.

Following stellar clinical data, Terns Pharmaceuticals' upsized $650M offering signals massive investor confidence and funds its push to disrupt the CML market.

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

A $900k stock grant to a new exec reveals more than a salary. It's a look into biotech's talent war and the financial tools used to secure human assets.